Magnetic nanoparticles coated with cyclodextrins and citrate for irinotecan delivery

• Autor(a) principal: Ana Paula de Figueiredo Monteiro
• Data de Publicação: 2017
• Outros Autores: Larissa Durães Caminhas, José Domingos Ardisson, Roberto Magalhães Paniago, María Esperanza Cortés Segura, Rubén Dario Sinisterra Millán
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.1016/j.carbpol.2016.11.091; http://hdl.handle.net/1843/61673; https://orcid.org/0000-0002-4202-1964; https://orcid.org/0000-0001-7657-9360; https://orcid.org/0000-0002-5615-3482; https://orcid.org/0000-0002-0540-7163; https://orcid.org/0000-0002-0560-8491; https://orcid.org/0000-0001-7656-1849
• topic: Cancer; Citrate; Cyclodextrin; Irinotecan; Magnetic nanoparticle; Ciclodextrinas; Nanopartículas; Sistemas de distribuição de medicamentos; Câncer - Tratamento; Potencial zeta; Luz - Espalhamento; Termogravimetria; Microscopia eletrônica - Técnica; Raios X - Difração; Fourier, Espectroscopia de infravermelho por transformada de

In the present work, we study the role of different components in the formation of more stable iron oxide magnetic nanoparticles (MNPs): β-cyclodextrin (BCD), 2-hydroxypropyl-β-cyclodextrin (HP) and citrate anion. MNPs formulations were characterized by FTIR, particles size measurements, zeta potential based on dynamic light scattering principle technique, X-ray powder pattern diffraction, XPS spectroscopy, transmission electron microscopy and thermogravimetric analysis. The results showed that cyclodextrins and citrate plays a key role in order to obtain a lower size of coated MNPs and proved to be an efficient strategy to obtain a more stable colloidal dispersion, avoiding the nanoparticles oxidation, enhancing the irinotecan incorporation and release. Furthermore, citrate-coated BCD-MNPs showed the same cytotoxicity of the free IRI.